The Food and Drug Administration (FDA) has expanded the indication of Cyramza (ramucirumab; Eli Lilly) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Its expanded approval for treatment of metastatic NSCLC in combination with docetaxel is based on a clinical trial of patients with previously treated and progressive lung cancer (n=1,253).
Patients were randomized to Cyramza plus docetaxel or a placebo plus docetaxel. Study results showed that half of the patients treated with Cyramza plus docetaxel survived an average of 10.5 months vs. 9.1 months for half of the patients in the placebo plus docetaxel group.
Continue Reading
RELATED: Rociletinib May Be Safe, Effective for the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Cyramza, a human IgG1 monoclonal antibody, is already indicated for treatment of advanced or metastatic, gastric, or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
For more information call (800) 545-5979 or visit Cyramza.com.
This article originally appeared on MPR
